Competitive Inhibition Assays. mAb Q5/13 conjugated to HP (HP-Q5/13) was prepared according to Harper and Orengo (11) .
Inhibition of Binding of Q5/13 to Anti-Idiotypic Serum 3496 by Human Ia Molecules. A limiting
dilution of HP-Q5/13 was mixed in a final volume of 50 /~1 with the indicated amounts of either immunologically active human Ia molecules purified by high performance liquid chromatography (L. E. Walker, unpublished data) or purified fl~-microglobulin (Immunochemical Engineering, Inc., Minneapolis, MN). After incubating overnight at 4°C, the mixture was allowed to react at 4°C for 3 h in wells coated with anti-idiotypic serum 3496 diluted 1/2,000.
After extensive washing, the bound HP activity was measured as described above. Tests were done in triplicate. Results are expressed as percent inhibition of the binding of HP-Q5/13 in the presence of Ia molecules, as compared with the maximum binding observed in wells to which no inhibitor was added. In the wells lacking inhibitor, A492 averaged 0.400, i.e., >10 times the reading of blank background wells. Inhibition of Binding of Q5/13 to Anti-ldiotypic Serum 3496 by Other rnAb. This assay was performed as described above, with the following modifications: 25 #1 of a limiting dilution of HP-Q5/13 was mixed with an equal amount of mAb (either ascites fluid or 10 × concentrated hybridoma supernatant) rather than with purified Ia. The first overnight incubation was omitted. Most of the antibodies obtained from other laboratories were understandably received in limited quantities and in a nonpurified form, either as ascitic fluid or hybridoma supernatant; consequently, it was not possible to test them quantitatively. However, because stoichiometry of idiotype-anti-idiotype binding indicated that 1 ng of Q5/13 idiotype could induce 50% inhibition of binding (data not shown), we estimate that each mAb was tested at a concentration at least 100-fold greater than that of Q5/13 idiotype.
Results and Discussion
Rabbit antiserum 3496 to the murine mAb Q5/13, specific for HLA-DR monomorphic determinants, was effectively rendered idiotype specific by appropriate absorptions as it markedly bound to Q5/13, but failed to react with either pooled normal mouse gamma globulin or antibodies sharing isotype, allotype, or MOPC21 determinants with Q5/13. Idiotypic determinants recognized by this antiserum were shown to be associated with the antigen-combining site of Q5/13 by the results of two independent sets of experiments: (a) anti-idiotypic antibodies were able to completely block the binding of Q5/13 to Ia-positive target cells ( Fig. l a) ; (b) conversely, purified human Ia molecules inhibited the binding of enzyme-linked Q5/13 to microtiter wells coated with anti-idiotype 3496 ( Fig. 1 b) . In both instances, the inhibitions were specific because antiserum 3496 did not affect the binding of HLA-A,B monoclonal antibodies to target cells, and the binding of Q5/13 to anti-idiotype 3496 was not diminished by either a control protein ( Fig. 1 b) or cell lysates from Ia-negative human lymphoid cells (data not shown).
We examined the presence of Q5/13 idiotype on other anti-Ia mAb to ascertain the degree of idiotypic relatedness among antibody molecules obtained from different immunizations and fusion experiments. As indicated in Table I , three mAb (417.1, CA2.206, and Q2/80), when tested for competitive inhibition of binding of Q5/13 idiotype to anti-idiotype 3496, were found to be inhibitory and, therefore, shared idiotype with Q5/13. These mAb were all directed against monomorphic Ia determinants. In contrast, none of five mAb directed to Ia polymorphic specificities inhibited the binding reaction (Table I) . Inhibition by mAb CA2.206 was not complete, even with 100-fold excess amounts, indicating only partial idiotype crossreactivity with Q5/13. Interestingly, not only were the four mAb bearing similar idiotypes obtained in distinct fusion experiments, but in one instance, Q2/80, the donor mouse was of NZB/W strain, as opposed to the BALB/c strain donors for the other three antibodies.
To confirm and further define the idiotype cross-reactivities observed, we tested the ability of antiserum 3496 to inhibit the binding of mAb to target cells (Table I) . Thus, the binding of both mAb 417.1 and CA2.206 was inhibited, the latter to a similar extent as in the competitive binding assay, demonstrating sharing of idiotype at the level of the antigen-combining site. In contrast, the binding of Q2/80 to target cells was not affected by antiserum 3496, indicating that this assay system is highly discriminating and that Q2/80 bears a Q5/13 idiotype, however, not in association with its antigen-combining site. These data are consistent with the possibility that the mouse antibody response to human Ia antigens is based upon a discrete number of recurrent idiotypes. This interpretation needs to be confirmed by examining the idiotypes of those anti-Ia mAb that do not bear the Q5/13 idiotype. It is possible that the techniques that are used to generate hybridomas may introduce a bias towards certain idiotypes; however, this does not seem to be the case here because preliminary data indicate that the Q5/13 idiotype is found as a significant component in the serum of both BALB/c and NZB/W mice immunized against human Ia-positive cells, Results similar to ours have been reported in the homologous murine Ia system. Thus, the idiotype of a mAb to Ia.7, a monomorphic specificity of murine I-E molecules, was readily detectable in anti-Ia.7 alloantisera (12) . Similarly, idiotypic cross-reactivity among mAb directed to monomorphic but not polymorphic specific: ities of Ia k has been recently reported (13) . Taken together, these observations suggest that Ia monomorphic determinants stimulate antibody-forming cells displaying related idiotypes.
It is tempting to propose that mAb Q5/13, 417.1, and CA2.206 define a monomorphic Ia specificity because their shared idiotype is associated with the antigencombining site. However, one has to critically evaluate this conclusion because a shared idiotype at the level of the antigen-combining site may (3, 14, 15) or may not (16, 17) relate directly to a particular epitope specificity. Conversely, idiotype sharing between Q5/13 and Q2/80, restricted to determinants outside the antigen-combining site, does not definitively rule out the possibility that Q5/13 and Q.2/80 may react with a similar Ia antigenic site. Verification of such an association in the human Ia system is especially hampered by the lack of definition of private and public Ia specificities. Nevertheless, by using Western blotting techniques, we demonstrated additional similarities among the reactivity patterns of Q5/13, 417.1, and CA2.206, i.e., they all react with an epitope that is located on the Ia fl subunit and is resistant to subunit dissociation (V. Q uaranta, unpublished work). Because of their differential reactivity with antiserum 3496 (See Table I ), Q5/13 and CA2.206 may be directed to overlapping but not identical antigenic sites.
The frequency of the Q5/13 idiotype among anti-Ia mAb from separate immunizations may either be the effect of human Ia molecule domains immunodominant to the mouse antibody response or it may represent an integral part of a regulatory idiotype pathway (18) in the mouse immune system. Determining whether or not mAb Q5/13, 417.1, CA2.206, and Q2/80 react with the same or similar epitopes will help in distinguishing between these two alternatives. It is possible that both of them might turn out to be correct.
A potential application of anti-idiotypic serum 3496 is as a probe of recognition units for Ia antigens on T cells. Thus, the role of Ia monomorphic determinants in immune cell interplays could be elucidated. In this regard, it is relevant that Q5/13 has an inhibitory effect both on allogeneic and autologous mixed lymphocyte reactions (19) . Consequently, alloreactive and autoreactive T cells may recognize the Q5/13 monomorphic determinant and possibly bear idiotypic structures similar to the Q5/13 idiotype.
Summary
We report a recurrent idiotype on a remarkably high fraction (4/19) of murine monoclonal antibodies specific for human Ia monomorphic determinants and elicited by separate immunizations. For three of them, the shared idiotype is associated with the antigen-combining site. These results indicate that the spectrum of mouse antibody responses to human Ia antigens may be based on recurrent idiotypes, suggesting a limited potential repertoire of murine monoclonal antibodies to human Ia antigens. Anti-idiotypic reagents might be helpful in dissecting this repertoire and to generate a mirror image of a human Ia antigenic map. Furthermore, antisera to the idiotype of antibodies specific for human Ia monomorphic determinants might help in elucidating the interactions between Ia molecules and receptors on immune cells.
